The approval of Leclaza plus Rybrevant combination therapy in South Korea has expanded treatment options for patients with non-small cell lung cancer (NSCLC). As Leclaza combination therapy has shown a positive overall survival (OS) result, it is highly likely to be the first-line standard therapy for treating EGFR-positive NSCLC.

According to industry resources on January 13, the Ministry of Food and Drug Safety (MFDS) granted approval for Leclaza plus Rybrevant combination therapy as the first-line treatment for EGFR-positive NSCLC. Following the approval, Leclaza plus Rybrevant combination therapy can be used in adult patients with advanced or metastatic NSCLC who have EGFR exon 19 deletion mutation